RISalud-ANDALUCÍA
Not a member yet
18682 research outputs found
Sort by
Accidentabilidad: accidentes de tráfico en Andalucía. Informe del año 2022
No full textEstudio descriptivo de la accidentabilidad por tráfico en Andalucía en el periodo 2000-2019. Análisis de la situación actual, evolución temporal y factores de riesgo estratificando por grupos de edad, sexo, y provincia. Se han utilizado las siguientes fuentes de información: Dirección General de Tráfico, Instituto de Estadística y Cartografía de Andalucía y Conjunto mínimo Básico de datos.Ye
Guía para la evaluación económica de medicamentos: propuesta del Comité Asesor para la Financiación de la Prestación Farmacéutica del Sistema Nacional de Salud español
No full textIn 2023, the General Directorate of Pharmacy of the Ministry of Health commissioned the Advisory Committee on the Financing of Pharmaceuticals for the National Health System (CAPF, Comité Asesor para la Financiación de la Prestación Farmacéutica del Sistema Nacional de Salud) to produce a guideline for the evaluation of the efficiency of medicines. The aim of this methodological note is to present their main points. The guideline includes 17 dimensions that an economic evaluation of medicines must encompass, the design of a reference case, and a checklist for evaluating the methodological quality and reporting. This guideline should serve as a foundational document for reforming the health technologies evaluation processes of the Ministry of Health. The guideline can also assist researchers, public health professionals, health technology companies and decision makers in assessing the validity of findings and conclusions from health economic evaluations.En el año 2023, la Dirección General de Farmacia del Ministerio de Sanidad encargó al Comité Asesor para la Financiación de la Prestación Farmacéutica del Sistema Nacional de Salud (CAPF) la realización de una guía para facilitar la evaluación de la eficiencia de los medicamentos. El objetivo de esta nota metodológica es presentar los principales puntos que desarrolla. La guía incluye 17 dimensiones que debe incluir una evaluación económica de medicamentos, diseñando un caso de referencia y definiendo una lista de comprobación para evaluar la calidad metodológica y su presentación. Esta guía debe servir como documento básico para el Ministerio de Sanidad en la reforma de los procesos de evaluación de tecnologías sanitarias. La guía también puede ayudar a investigadores, profesionales de la salud pública, empresas de tecnología sanitaria y personas encargadas de tomar decisiones a evaluar la validez de los hallazgos y de las conclusiones de las evaluaciones económicas en salud.Ye
Treatment of hospitalized patient with hyperglycemia: An EFIM critically appraised and adapted guideline
No full textOver the past decade, diabetes mellitus (DM) has emerged as a growing epidemic, with a direct link to an increased risk of hospitalization and a strong effect of glycemic control on clinical outcomes. The aim of this document was to critically appraise and adapt existing clinical practice guidelines (CPGs) to provide specific recommendations for the management of hyperglycemia in hospitalized adults with and without previously known DM, in an attempt to provide a practical tool to reduce the risk of major in-hospital complications. The first step of the adaptation process was to identify unsolved clinical questions (PICOs) in hospitalized persons with hyperglycemia. This was followed by a critical appraisal of updated existing CPGs and the selection of recommendations that were most applicable to specific clinical situations. From the four updated high-quality evidence-based CPGs, 75 recommendations were selected, focusing on five common clinical scenarios in real-world practice: 1) glycemic targets; 2) persons with comorbidities; 3) elderly adults with low consciousness or dementia with irregular feeding or parenteral/enteral nutrition; 4) special hyperglycemic scenarios (stress hyperglycemia, corticosteroid treatment, fasting); and 5) glucose-lowering therapy at discharge. Of the 75 selected recommendations (59 strong and 16 weak), 37 were based on high-quality evidence, 8 on moderate-quality evidence, and 17 on low-quality evidence, while 13 were based on consensus (best practice statements). The recommendations apply to adults who are hospitalized or discharged from the hospital. Using a systematic methodology, this guideline provides an updated and ease-to-use tool for the management of hospitalized adults with hyperglycemia.Ye
Treatment of hospitalized patient with hyperglycemia: An EFIM critically appraised and adapted guideline
No full textOver the past decade, diabetes mellitus (DM) has emerged as a growing epidemic, with a direct link to an increased risk of hospitalization and a strong effect of glycemic control on clinical outcomes. The aim of this document was to critically appraise and adapt existing clinical practice guidelines (CPGs) to provide specific recommendations for the management of hyperglycemia in hospitalized adults with and without previously known DM, in an attempt to provide a practical tool to reduce the risk of major in-hospital complications. The first step of the adaptation process was to identify unsolved clinical questions (PICOs) in hospitalized persons with hyperglycemia. This was followed by a critical appraisal of updated existing CPGs and the selection of recommendations that were most applicable to specific clinical situations. From the four updated high-quality evidence-based CPGs, 75 recommendations were selected, focusing on five common clinical scenarios in real-world practice: 1) glycemic targets; 2) persons with comorbidities; 3) elderly adults with low consciousness or dementia with irregular feeding or parenteral/enteral nutrition; 4) special hyperglycemic scenarios (stress hyperglycemia, corticosteroid treatment, fasting); and 5) glucose-lowering therapy at discharge. Of the 75 selected recommendations (59 strong and 16 weak), 37 were based on high-quality evidence, 8 on moderate-quality evidence, and 17 on low-quality evidence, while 13 were based on consensus (best practice statements). The recommendations apply to adults who are hospitalized or discharged from the hospital. Using a systematic methodology, this guideline provides an updated and ease-to-use tool for the management of hospitalized adults with hyperglycemia.Ye
Vol. 29, nº 15. Cryptosporidium spp. en Andalucía, 2003-2023. Análisis descriptivo
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 14/2024 y acumulado desde la semana 01/2024. Datos provisionales. Incluye además el artículo titulado “Cryptosporidium spp. en Andalucía, 2003-2023. Análisis descriptivo”, de “Sheila López Moreira, Alejandro Vila Perez, Cristina Jiménez Biedma”.Ye
Vol. 29, nº 48. VIH/SIDA en Andalucía. Año 2023.
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 47/2024 y acumulado desde la semana 01/2024. Datos provisionales. Incluye además el artículo titulado “VIH/SIDA en Andalucía. Año 2023”, de “Ligia Elena González Serrano, Isabel Mª Vázquez Rincón, Nicola Lorusso, Juan Carlos Carmona Lagares”.N
Vol. 29, nº 40. Presencia de bacterias multirresistentes en las personas institucionalizadas en residencias de mayores de los distritos Granada y metropolitano de Granada.
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 39/2024 y acumulado desde la semana 01/2024. Datos provisionales. Incluye además el artículo titulado “Presencia de bacterias multirresistentes en las personas institucionalizadas en residencias de mayores de los distritos Granada y metropolitano de Granada”, de “Carla Torralba Suárez, Juan Castilla Heredia, Begoña López Hernández ”.N
Adiposity assessed close to diagnosis and prostate cancer prognosis in the EPIC study.
No full textBackground: Adiposity has been characterized as a modifiable risk factor for prostate cancer. Its association with outcomes after prostate cancer diagnosis, however, must be better understood, and more evidence is needed to facilitate the development of lifestyle guidance for patients with prostate cancer.
Methods: We investigated the associations between adiposity indices close to prostate cancer diagnosis (up to 2 years before or up to 5 years after diagnosis) and mortality in 1968 men of the European Prospective Investigation into Cancer and Nutrition cohort. Men were followed up for a median of 9.5 years. Cox proportional hazards models were adjusted for age and year of diagnosis, disease stage and grade, and smoking history and stratified by country.
Results: Each 5-unit increment in prediagnosis or postdiagnosis body mass index combined was associated with a 30% higher rate of all-cause mortality and a 49% higher rate of prostate cancer-specific mortality. Similarly, each 5-unit increment in prediagnosis body mass index was associated with a 35% higher rate of all-cause mortality and a 51% higher rate of prostate cancer-specific mortality. The associations were less strong for postdiagnosis body mass index, with a lower number of men in analyses. Less clear positive associations were shown for waist circumference, hip circumference, and waist to hip ratio, but data were limited.
Conclusions: Elevated levels of adiposity close to prostate cancer diagnosis could lead to higher risk of mortality; therefore, men are encouraged to maintain a healthy weight. Additional research is needed to confirm whether excessive adiposity after prostate cancer diagnosis could worsen prognosis.This work was supported by the World Cancer Research Fund network of charities (American Institute for Cancer Research, World Cancer Research Fund, and Wereld Kanker Onderzoek Fonds). The coordination of EPIC is financially supported the International Agency for Research on Cancer and by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, which has additional infrastructure support provided by the National Institute for Health and Care Research Imperial Biomedical Research Centre. The national cohorts are supported by the Danish Cancer Society; German Cancer Aid, German Cancer Research Center, German Institute of Human Nutrition Potsdam-Rehbruecke, Federal Ministry of Education and Research (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo, and National Research Council (Italy); Health Research Fund, Institute of Health Carlos III, and the regional governments of Andaluc�ıa, Asturias, Basque Country, Murcia, and Navarra, and the Catalan Institute of Oncology (Spain); and Cancer Research UK (C864/A14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (MR/N003284/1, MCUU_12015/1 and MC_UU_00006/1 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford) (United Kingdom). R. Zamora-Ros was supported by the Miguel Servet II (CPII20/ 00009) program from Institute of Health Carlos III (co-funded by the European Social Fund investing in your future). The open access fee was paid from the Imperial College London Open Access Fund.Ye
Vol. 29, nº 03. Asociación entre metales pesados tóxicos y el riesgo de desarrollar cáncer de mama
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 02/2024 y acumulado desde la semana 01/2024. Datos provisionales. Incluye además el artículo titulado “Asociación entre metales pesados tóxicos y el riesgo de desarrollar cáncer de mama”, de “Laura Leyva Valverde”.Ye
Vol. 29, nº 51. Índice de artículos del boletín semanal (BES) del SVEA publicados en 2024
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 50/2024 y acumulado desde la semana 01/2024. Datos provisionales. Incluye además el artículo titulado “Índice de artículos del boletín semanal (BES) del SVEA publicados en 2024”.N